Abstract: The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.
Type:
Grant
Filed:
July 28, 2011
Date of Patent:
January 10, 2017
Assignee:
Neuralstem, Inc.
Inventors:
Woei-Cherng Shyu, Shinn-Zong Lin, Hsiao-Jung Wang, Karl K. Johe
Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R3 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.
Abstract: The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.
Abstract: Disclosed herein are methods for identifying an agent for treating or preventing neurogenerative disease and to methods for recapitulating tauopathies using a tau protein that includes at least four different mutations that cause the condition frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and to nucleic acids encoding the tau protein.
Type:
Grant
Filed:
April 28, 2011
Date of Patent:
December 27, 2016
Assignee:
Universitaet Leipzig
Inventors:
Andrea Robitzki, Heinz-Georg Jahnke, Dana Krinke, Frank Striggow, Till Mack
Abstract: Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.
Type:
Grant
Filed:
July 31, 2015
Date of Patent:
December 13, 2016
Assignee:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
Type:
Grant
Filed:
September 14, 2012
Date of Patent:
December 13, 2016
Assignee:
AXON NEUROSCIENCE SE
Inventors:
Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka
Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
Type:
Grant
Filed:
June 29, 2012
Date of Patent:
December 13, 2016
Assignee:
CENTRO DE INGENIERÍA GENÉTICA Y BIOTECHNOLOGÍA
Inventors:
Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura
Abstract: Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays.
Type:
Grant
Filed:
May 18, 2012
Date of Patent:
November 29, 2016
Assignee:
Oligomerix, Inc.
Inventors:
James G. Moe, Eliot J. Davidowitz, Patricia Lopez
Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
November 22, 2016
Assignee:
Sangamo BioSciences, Inc.
Inventors:
Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
Abstract: Provided herein are anti-human alpha-synuclein antibodies, including, for example, antibodies that bind to human alpha-synuclein which has a free N-terminal methionine residue, and methods of using the same.
Type:
Grant
Filed:
November 20, 2014
Date of Patent:
November 15, 2016
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
Abstract: Embodiments of the technology described herein relate, at least in part, to methods of modulating the activity of a neuron by contacting the neuron with a photo-sensitive TrpA1 agonist and then illuminating the neuron with electromagnetic radiation. Also described herein are photo-sensitive TrpA1 agonists.
Type:
Grant
Filed:
June 13, 2012
Date of Patent:
November 8, 2016
Assignee:
The General Hospital Corporation
Inventors:
Randall Peterson, Chung Yan J. Cheung, David Kokel
Abstract: The present invention provides a method of using indole-ketone or indolidone such as SU4312, SU5416, SU11248 (Sunitinib), or indirubin-3-oxime to treat a neurodegenerative disease or disorder such as Parkinson's disease which is associated with excessive neuronal Nitric Oxide Synthase (nNOS) activity.
Type:
Grant
Filed:
October 25, 2012
Date of Patent:
November 8, 2016
Assignees:
UNIVERSITY OF MACAU, THE HONG KONG POLYTECHNIC UNIVERSITY
Inventors:
Ming Yuen Lee, Yifan Han, Chung Lit Choi, Zaijun Zhang, Wei Cui
Abstract: The present invention relates to the provision of immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
Type:
Grant
Filed:
October 7, 2014
Date of Patent:
November 1, 2016
Assignee:
Pfizer Vaccines LLC
Inventors:
Brian Robert Champion, Leonard Gabriel Contillo, Jr., Michael Dale Eisenbraun, James Downey Fraser, Julie Jia Li Hawkins, James Richard Merson, Brian Gregory Pierce, Xiayang Qiu, Jakir Hussain Ullah, David Michael Wyatt
Abstract: A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.
Type:
Grant
Filed:
January 27, 2014
Date of Patent:
October 18, 2016
Assignee:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors:
Changjoon Justin Lee, Seonmi Jo, Boeun Yoon, Hyunah Choo, Ji Yoon Kim, Daesoo Kim
Abstract: A PAT nonapeptide of formula EAKSQGGSD (SEQ ID NO: 1) can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes.
Type:
Grant
Filed:
November 2, 2015
Date of Patent:
October 18, 2016
Assignee:
ORPHIT
Inventors:
Claude Laruelle, Jamal Temsamani, Frederic Mourlane
Abstract: Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof.
Type:
Grant
Filed:
November 3, 2014
Date of Patent:
October 11, 2016
Assignees:
University of Central Florida Research Foundation, Inc., University of L'Aquila
Inventors:
Sudipta Seal, Soumen Das, Annamaria Cimini, Barbara D'Angelo
Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.
Type:
Grant
Filed:
June 11, 2014
Date of Patent:
September 27, 2016
Assignees:
BIONURE FARMA, S.L., INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PII SUNYER (IDIBAPS) (undivided 30% interest), CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (individed 20% interest)
Abstract: This invention concerns affinity tools for oligomeric forms of tau protein. It relates to the field of neurodegeneration, more particularly to the field of tau-related diseases and tauopathy. The invention provides novel tau antibodies and antibody fragments, nucleic acids encoding such antibodies and antibody fragments, cell lines producing such antibodies and antibody fragments, antibody compositions, and kits for the detection of aggregated tau and for the diagnosis of diseases involving aggregated tau. The invention further provides methods for the detection of aggregated tau, for the diagnosis of diseases involving aggregated tau, and for the identification of compositions interfering with the formation and/or stability of tau aggregates.
Type:
Grant
Filed:
July 16, 2012
Date of Patent:
September 20, 2016
Assignees:
KATHOLIEKE UNIVERSITEIT LEUVEN, KU RESEARCH & DEVELOPMENT, FUJIREBIO EUROPE N.V.
Inventors:
Joris Winderickx, Eugeen Vanmechelen, Fred Van Leuven